RAD101

Radiopharmaceutical

Phase 2topline reported

Evidence outlook

Brain Metastases: topline reported 2026-07-22

The sponsor reported topline results on 2026-07-22 (RAD101 Phase 2b meets primary endpoint). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Brain Metastases

Competitive landscape

Other Fatty acid synthase (FASN) drugs

Denifanstat, CMS121. Compare all 3 Fatty acid synthase (FASN) drugs

2 other tracked programmes target this mechanism, 1 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
RAD101: this drugPhase 2RadiopharmaceuticalFatty acid synthase (FASN)not yet gradedNo reviewed efficacy summary
Denifanstat
Phase 3(overall)
Small moleculeFatty acid synthase (FASN), FASNReliable signal
NCT04906421: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score). (52 Weeks): ITT: TVB-2640 50 mg 42/112 | mITT: TVB-2640 50 mg 42/81 vs ITT: Placebo 9/56 | mITT: Placebo 9/45
NCT03938246: Relative change in liver fat (MRI-PDFF) at week 12 vs placebo (+4.5%): -9.6% with 25 mg (LS mean difference -15.5%; 95% CI -31.3 to -0.23; P=.053) and -28.1% with 50 mg (LS mean difference -28.0%; 95% CI -44.5 to -11.6; P=.001) (FASCINATE-1, Gastroenterology 2021).
CMS121
Phase 1(overall)
Small moleculeFatty acid synthase (FASN), Fatty acid synthase (FASN)Weak signalFeatured results are safety only

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 July 2026Topline resultRAD101 Phase 2b meets primary endpoint
US · Radiopharm Theranostics, Ltd · Source ↗